SlideShare a Scribd company logo
Breakthrough to achieve long-term survival
DSA & HCV in liver transplantation
Audrey Coilly, MD
Centre Hepato-Biliaire
Paul Brousse Hospital, Villejuif, France
DISCLOSURES
Audrey Coilly, MD
Centre Hepato-Biliaire
AP-HP Hopital Paul-Brousse, Villejuif, France
I have relevant financial relationships with respect to the content of this
session as follows:
1.Speaker Bureau: Gilead France
2.Grant: Novartis France
3.Consultancy and Teaching: Astellas, MSD, BMS, Janssen
How to improve long term survival in liver transplantation?How to improve long term survival in liver transplantation?
Watt, KD. Am J Transpl. 2010Watt, KD. Am J Transpl. 2010
% death according to time after liver
transplantation
% death according to time after liver
transplantation
50%
20%
• Register study, n=798
How to improve long term survival in liver transplantation?How to improve long term survival in liver transplantation?
Watt, KD. Am J Transpl. 2010Watt, KD. Am J Transpl. 2010
• Register study, n=798
• From 8-years post-LT, the
first cause of death is
liver-related
HCV recurrence is the first cause of death and graft loss when patients
are transplanted with a positive HCV RNA
HCV recurrence is the first cause of death and graft loss when patients
are transplanted with a positive HCV RNA
Forman, LM. Gastroenterology. 2002Forman, LM. Gastroenterology. 2002
Patient survival Graft survival
11,036 patients (UNOS registry)
11,791 LT from 1992 to 1998
1.00
0.75
0.50
0.25
0.00
1 2 3 4 5
Follow-up (years)
Proportionofpatientssurviving
Log-rank X2
=19.7
P<0.0001
HCV -
HCV +
1.00
0.75
0.50
0.25
0.00
1 2 3 4 5
Follow-up (years)
HCV -
HCV +
Log-rank X2
=52.85
P<0.0001Proportionofallograftssurviving
0 0
• The detrimental effects of DSA on outcomes following solid organ
transplantation have been known for many years1
• Liver transplantation is an exception but some evidence has been recently
highlighted, showing that DSA could be associated with2
:
Spectrum of diseases related to donor-specific HLA alloantibodies (DSA)
in liver transplantation
Spectrum of diseases related to donor-specific HLA alloantibodies (DSA)
in liver transplantation
1- Angaswamy, N. Human Immunology. 2013 2- O’Leary, JG. Am J Transpl. 20141- Angaswamy, N. Human Immunology. 2013 2- O’Leary, JG. Am J Transpl. 2014
1. What are the prevalence and incidence of DSA after LT and
are they impacted by HCV replication?
2. How to diagnose acute antibody-mediated rejection (AMR)?
When associated with HCV recurrence?
3. What are the consequences of DSA on LT outcomes and on
HCV recurrence?
4. How to prevent? When and How to treat AMR?
AgendaAgenda
1. What are the prevalence and incidence of DSA after LT and
are they impacted by HCV replication?
2. How to diagnose acute antibody-mediated rejection (AMR)?
When associated to HCV recurrence?
3. What are the consequences of DSA on LT outcomes and on
HCV recurrence?
4. How to prevent? When and How to treat AMR?
AgendaAgenda
Preformed DSA is quite common in LT contextPreformed DSA is quite common in LT context
1- Castillo-Rama, M. Liver Transpl. 2008 2- Kozlowski, T. Liver Transpl. 2011 3- Muro, M. Transpl Immuno.
2005 4- Fontana, M. Transpl Int. 2010 5- Taner, T. Am J Transpl. 2012
1- Castillo-Rama, M. Liver Transpl. 2008 2- Kozlowski, T. Liver Transpl. 2011 3- Muro, M. Transpl Immuno.
2005 4- Fontana, M. Transpl Int. 2010 5- Taner, T. Am J Transpl. 2012
• Several reports of monocentric, retrospective, cross-match
studies in liver transplant recipients showed prevalence of
DSA ranging from 5.2% to 24.2%1-4
• A prospective monocentric study5
was consistent with these
reports, as DSA was found in 22.2%
In most cases, preformed DSA disappear after liver transplantationIn most cases, preformed DSA disappear after liver transplantation
1- Taner, T. Am J Transpl. 2012 2- Dar, W. Am J Transpl. 20111- Taner, T. Am J Transpl. 2012 2- Dar, W. Am J Transpl. 2011
Among the 20 patients, only 3
had persistent DSA at 4 months
post-LT1
Some reports suggest that Class
I DSA were preferentially
cleared*2
*In recipients of SLKT
While preformed DSA disappear,
liver recipients may develop de novo DSA
While preformed DSA disappear,
liver recipients may develop de novo DSA
1- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 20141- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 2014
• In a large retrospective cohort study of 749 liver transplant recipients,
8.1% developed de novo DSA 1 year post-LT1
• Another large retrospective study enrolling 267 patients have shown an
incidence of de novo DSA of 9.1% (median follow-up: 110 months)2
• In both studies, de novo DSA were mainly Class II DSA (Anti-DQ)
Risk factors of de novo DSA appearanceRisk factors of de novo DSA appearance
1- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 20141- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 2014
At one year post-LT1
In the French study, the sole predictive factor for the emergence of de
novo DSAs was retransplantation (OR 3.75; 95% CI 1.28-11.05, p=0.025)2
Risk factors of de novo DSA appearanceRisk factors of de novo DSA appearance
1- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 20141- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 2014
At one year post-LT1
In the French study, the sole predictive factor for the emergence of de
novo DSAs was retransplantation (OR 3.75; 95% CI 1.28-11.05, p=0.025)2
Risk factors of de novo DSA appearanceRisk factors of de novo DSA appearance
1- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 20141- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 2014
At one year post-LT1
In the French study, the sole predictive factor for the emergence of de
novo DSAs was retransplantation (OR 3.75; 95% CI 1.28-11.05, p=0.025)2
• None of these studies have shown differential prevalence or incidence of
DSA in HCV positive patients
• The use of pegylated interferon α was not a predictor of DSA appearence2
1. What are the prevalence and incidence of DSA after LT and
are they impacted by HCV replication?
2. How to diagnose acute antibody-mediated rejection (AMR)?
When associated with HCV recurrence?
3. What are the consequences of DSA on LT outcomes and on
HCV recurrence?
4. How to prevent? When and How to treat AMR?
AgendaAgenda
The diagnosis of AMR is challengingThe diagnosis of AMR is challenging
• Abnormalities of liver test are inconstant and non specific
• In the majority of patients, the presence of DSA is not
associated with rejection
– Variability of DSA testing techniques
– Screening: Solid-phase immunoassays (Luminex®)
– The presence and specificity of antibodies is then detected
using a spectrophotometer
– The mean fluorescence intensity (MFI) allows a
normalization and a quantification of the results
There is no consensus concerning threshold of MFI to be considered
positive
There is no consensus concerning threshold of MFI to be considered
positive
Musat, AI. Liver Transpl. 2013Musat, AI. Liver Transpl. 2013
• Ranging from >300 to >10 000
• Prospective study enrolling 109 LT patients
– Aimed to determine cut-off of MFI with the best PPV and NPV for
acute rejection (<90d post-LT)
-- Class I or II MFI≥300
-- Class I and II MFI<300
Pathological examination is important to assess diagnosis of AMRPathological examination is important to assess diagnosis of AMR
O’Leary, JG. Liver Transpl. 2014O’Leary, JG. Liver Transpl. 2014
• Until recently, there was no consensus concerning histological fearures of
AMR
• Most of the time, AMR is followed by ACR
AMR - ACRAMR - ACR
Persistent ARPersistent AR
Chronic rejectionChronic rejection
Graft LossGraft Loss
« acute-AMR score » « acute-AMR score » 
O’Leary, JG. Liver Transpl. 2014O’Leary, JG. Liver Transpl. 2014
3 LT centers, 4 blinded pathologists
« acute-AMR score » « acute-AMR score » 
O’Leary, JG. Liver Transpl. 2014O’Leary, JG. Liver Transpl. 2014
3 LT centers, 4 blinded pathologists
Does C4d staining assist the histopathological diagnosis in liver 
transplantation?
Does C4d staining assist the histopathological diagnosis in liver 
transplantation?
1- Colvin, RB. J Am Soc Nephrol 2007 2- Bellamy CO. Histopathology. 2007 3- Jain, A. Clin transp. 2006
4- Bouron-Dal Soglio, D. Hum Pathol 2008 5- Lunz, J. Am J Transplant. 2012
1- Colvin, RB. J Am Soc Nephrol 2007 2- Bellamy CO. Histopathology. 2007 3- Jain, A. Clin transp. 2006
4- Bouron-Dal Soglio, D. Hum Pathol 2008 5- Lunz, J. Am J Transplant. 2012
• C4d staining is well validated to 
diagnose AMR in kidney 
transplantation1
• In LT, interpretation of C4d staining 
and practical utility is less clear2
– More sensitive in fresh tissue
– C4d deposits are often seen in other 
liver insults as HCV recurrence3-4
• Only obvious and diffuse staining 
(strong portal vein, capillary, 
periportal sinusoids)5 O’Leary, JG. Liver Transplant. 2014
Finally, the diagnosis of AMR should be based on 4 criteriaFinally, the diagnosis of AMR should be based on 4 criteria
O’Leary, JG. Am J Transpl. 2014 – Meeting reportO’Leary, JG. Am J Transpl. 2014 – Meeting report
Expert opinion
1. Presence of DSA in serum
2. Histopathologic evidence of diffuse microvascular 
endothelial cell injury and microvasculitis
3. Strong and diffuse positivity of C4d staining in 
tissue
4. Exclusion of other causes of injury, including HCV 
related-injury
HCV recurrence could complicate the diagnosis of acute rejection and 
AMR
HCV recurrence could complicate the diagnosis of acute rejection and 
AMR
HCV Acute rejection
Portal injuries
Infiltrates ++ ++
Bile duct injury +/- ++
Endotheliitis - ++
Fibrosis +/++ -
Parenchymal injuries
Inflammation ++ +
Necrosis + -
Cholestasis - +
Central vein endotheliitis - +
Steatosis + -
Acknowledgements to Dr Sebagh MAcknowledgements to Dr Sebagh M
1. What are the prevalence and incidence of DSA after LT and 
are they impacted by HCV replication?
2. How to diagnose acute antibody-mediated rejection (AMR)? 
When associated with HCV recurrence?
3. What are the consequences of DSA on LT outcomes and on 
HCV recurrence?
4. How to prevent? When and How to treat AMR?
AgendaAgenda
De novo DSAs decrease both patient and graft survivalDe novo DSAs decrease both patient and graft survival
• Patients with de novo DSA develop AMR in 23.8%1
1- Del Bello, A. Am J Transpl. 2014 2- Kaneku, H. Am J Transpl. 20131- Del Bello, A. Am J Transpl. 2014 2- Kaneku, H. Am J Transpl. 2013
Patient survival2
Graft survival2
Available data concerning the impact of preformed DSA on graft and 
overall survival are contradictory
Available data concerning the impact of preformed DSA on graft and 
overall survival are contradictory
1- Gordon, RD. Surgery. 1986 2- Moore, SB. Transplant Proc. 1987 3- Ogura, K. Transplant Proc. 1992
4- Takaya, S. . Transplant Proc. 1991 5- Goh, A. Liver Transplant. 2010
6- Castillo-Rama, M. Liver Transpl. 2008
1- Gordon, RD. Surgery. 1986 2- Moore, SB. Transplant Proc. 1987 3- Ogura, K. Transplant Proc. 1992
4- Takaya, S. . Transplant Proc. 1991 5- Goh, A. Liver Transplant. 2010
6- Castillo-Rama, M. Liver Transpl. 2008
• Several ancient reports found that a positive cross-match was 
unrelated to LT outcomes1,2
• … But many others demonstrated an increased graft loss rates3-6
Class II DSA (preformed or de novo) are independent predictor of 
patient death and allograft loss
Class II DSA (preformed or de novo) are independent predictor of 
patient death and allograft loss
• Preformed class II DSA have been shown to be associated with early AR1
• In a monocentric retrospective study analyzing 86 SLKT patients2
, class II DSA 
(preformed or de novo) increased AMR and ACR of the liver and kidney 
grafts
1- O’Leary, JG. Liver Transpl. 2013 2- O’Leary, JG. Am J Transpl. 20131- O’Leary, JG. Liver Transpl. 2013 2- O’Leary, JG. Am J Transpl. 2013
DSA are associated with fibrosis progression in HCV positive recipientsDSA are associated with fibrosis progression in HCV positive recipients
• In this monocentric retrospective study analyzing 507 LT patients
• Preformed Class I and II DSAs were associated with lower survival
• de novo DSA are limit but unsignificant regarding fibrosis progression
O’Leary, JG. Liver Transplant. 2014O’Leary, JG. Liver Transplant. 2014
1. What are the prevalence and incidence of DSA after LT and
are they impacted by HCV replication?
2. How to diagnose acute antibody-mediated rejection (AMR)?
When associated with HCV recurrence?
3. What are the consequences of DSA on LT outcomes and on
HCV recurrence?
4. How to prevent? When and How to treat AMR?
AgendaAgenda
« Prevention is better than cure »: Before liver transplantation« Prevention is better than cure »: Before liver transplantation
1- Curry, MP. ILTS 2014. Oral #137 2- O’Leary, JG. Am J Transpl. 20131- Curry, MP. ILTS 2014. Oral #137 2- O’Leary, JG. Am J Transpl. 2013
HCV: Achieve SVR before LT
• Not always possible with
IFN-based regimen
• Most of patients will be
able to achieve SVR before
LT
• Post-LT SVR12: 70%
Preformed DSA
Liver transplant
(up to 48 weeks)
SOF 400 mg/day +
RBV 1000–1200 mg/day
SOF 400 mg/day +
RBV 1000–1200 mg/day
Undergoing LT
for HCC
2° to HCV1
N=61
Undergoing LT
for HCC
2° to HCV1
N=61
• Evidence does not advocate
to contraindicate LT when
there is a positive
crossmatch, nor to delay LT
awaiting the results
• Avoid preformed Class II
DSA in combined liver-
kidney transplantation
(MFI>10,000)2
« Prevention is better than cure »: After liver transplantation« Prevention is better than cure »: After liver transplantation
• In my opinion, treating HCV recurrence based on IFN-free regimen is
mandatory without waiting a significant fibrosis on the liver graft
Preformed DSA
Strict monitoring:
-Liver test when tapering IS
-Retest DSA: timing?
-Protocol liver biopsies: 1, 2 and 5 years
« Prevention is better than cure »: After liver transplantation« Prevention is better than cure »: After liver transplantation
• In my opinion, treating HCV recurrence based on IFN-free regimen is
mandatory without waiting a significant firbrosis on the liver graft
De novo or persistent DSA
*Anti-humoral agents and techniques as plasmapheresis, IV immune globuline, rituximab, bortezomib*Anti-humoral agents and techniques as plasmapheresis, IV immune globuline, rituximab, bortezomib
• The prevalence of preformed DSA is about 20% and the
incidence of de novo DSA is about 10% in LT
• DSA are associated with several graft diseases, mainly AMR
but diagnosis was made on histological features+/-C4d
staining
• De novo DSA and preformed class II DSA, especially with high
MFI, seem to pejoratively influence outcomes after LT
• When associated with HCV, DSA worsen fibrosis progression
• Thanks to antiviral IFN-free regimen, therapeutic strategies of
DSA positivity and/or AMR will not differ from HCV-
recipients, but need to be evaluated in prospective studies
ConclusionConclusion

More Related Content

What's hot

Les Alternative à la Transplantation Hépatique Cadavérique
Les Alternative à la Transplantation Hépatique CadavériqueLes Alternative à la Transplantation Hépatique Cadavérique
Les Alternative à la Transplantation Hépatique CadavériqueEric Vibert, MD, PhD
 
How to predict po course before and during surgery for HCC
How to predict po course before and during surgery for HCCHow to predict po course before and during surgery for HCC
How to predict po course before and during surgery for HCCEric Vibert, MD, PhD
 
Liver transplantation vs Resection in cholangiocarcinoma on cirrhosis
Liver transplantation vs Resection in cholangiocarcinoma on cirrhosisLiver transplantation vs Resection in cholangiocarcinoma on cirrhosis
Liver transplantation vs Resection in cholangiocarcinoma on cirrhosisEric Vibert, MD, PhD
 
Innovations in liver surgery for Hepatocellular Carcinoma
Innovations in liver surgery for Hepatocellular CarcinomaInnovations in liver surgery for Hepatocellular Carcinoma
Innovations in liver surgery for Hepatocellular CarcinomaEric Vibert, MD, PhD
 
Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015
Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015
Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015Eric Vibert, MD, PhD
 
Traitement Chirurgical HCC Conf Zurich
Traitement Chirurgical HCC Conf ZurichTraitement Chirurgical HCC Conf Zurich
Traitement Chirurgical HCC Conf ZurichEric Vibert, MD, PhD
 
Liver Transplantation with severe steatotic graft and postoperative organ dys...
Liver Transplantation with severe steatotic graft and postoperative organ dys...Liver Transplantation with severe steatotic graft and postoperative organ dys...
Liver Transplantation with severe steatotic graft and postoperative organ dys...Eric Vibert, MD, PhD
 
Arterial Lactate Concentration is a major pronostic factor after elective sur...
Arterial Lactate Concentration is a major pronostic factor after elective sur...Arterial Lactate Concentration is a major pronostic factor after elective sur...
Arterial Lactate Concentration is a major pronostic factor after elective sur...Eric Vibert, MD, PhD
 
Du 2016 tp biomarkers
Du 2016 tp biomarkersDu 2016 tp biomarkers
Du 2016 tp biomarkersodeckmyn
 
Liver Transplantation for Cholangiocarcinoma
Liver Transplantation for CholangiocarcinomaLiver Transplantation for Cholangiocarcinoma
Liver Transplantation for CholangiocarcinomaEric Vibert, MD, PhD
 
Samuel1 hbv lt du16
Samuel1 hbv lt du16Samuel1 hbv lt du16
Samuel1 hbv lt du16odeckmyn
 
4.11.15 GI Symposium
4.11.15 GI Symposium4.11.15 GI Symposium
4.11.15 GI SymposiumBeth Lynn
 
Portal Vein Embolization and colorectal liver met
Portal Vein Embolization and colorectal liver metPortal Vein Embolization and colorectal liver met
Portal Vein Embolization and colorectal liver metEric Vibert, MD, PhD
 
Room a a01. mcgee-aki update on biomarkers and dx (en)
Room a a01. mcgee-aki update on biomarkers and dx (en)Room a a01. mcgee-aki update on biomarkers and dx (en)
Room a a01. mcgee-aki update on biomarkers and dx (en)SoM
 

What's hot (20)

Les outils d'évaluation ( Volumetries, Pressions) - Dr Andrea Laurenzi - Pr ...
Les outils d'évaluation ( Volumetries, Pressions) - Dr Andrea Laurenzi - Pr ...Les outils d'évaluation ( Volumetries, Pressions) - Dr Andrea Laurenzi - Pr ...
Les outils d'évaluation ( Volumetries, Pressions) - Dr Andrea Laurenzi - Pr ...
 
Les Alternative à la Transplantation Hépatique Cadavérique
Les Alternative à la Transplantation Hépatique CadavériqueLes Alternative à la Transplantation Hépatique Cadavérique
Les Alternative à la Transplantation Hépatique Cadavérique
 
En pratique : Hépatectomie majeure ou "economique" quand les deux sont possi...
En pratique : Hépatectomie majeure ou "economique" quand les deux sont possi...En pratique : Hépatectomie majeure ou "economique" quand les deux sont possi...
En pratique : Hépatectomie majeure ou "economique" quand les deux sont possi...
 
How to predict po course before and during surgery for HCC
How to predict po course before and during surgery for HCCHow to predict po course before and during surgery for HCC
How to predict po course before and during surgery for HCC
 
Liver transplantation vs Resection in cholangiocarcinoma on cirrhosis
Liver transplantation vs Resection in cholangiocarcinoma on cirrhosisLiver transplantation vs Resection in cholangiocarcinoma on cirrhosis
Liver transplantation vs Resection in cholangiocarcinoma on cirrhosis
 
Resection early hcc
Resection early hccResection early hcc
Resection early hcc
 
Nouvellesapprochestherapeutiqueshepatitebmlevrero
NouvellesapprochestherapeutiqueshepatitebmlevreroNouvellesapprochestherapeutiqueshepatitebmlevrero
Nouvellesapprochestherapeutiqueshepatitebmlevrero
 
Innovations in liver surgery for Hepatocellular Carcinoma
Innovations in liver surgery for Hepatocellular CarcinomaInnovations in liver surgery for Hepatocellular Carcinoma
Innovations in liver surgery for Hepatocellular Carcinoma
 
Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015
Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015
Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015
 
Traitement Chirurgical HCC Conf Zurich
Traitement Chirurgical HCC Conf ZurichTraitement Chirurgical HCC Conf Zurich
Traitement Chirurgical HCC Conf Zurich
 
Liver Transplantation with severe steatotic graft and postoperative organ dys...
Liver Transplantation with severe steatotic graft and postoperative organ dys...Liver Transplantation with severe steatotic graft and postoperative organ dys...
Liver Transplantation with severe steatotic graft and postoperative organ dys...
 
Vte予防 講義
Vte予防 講義Vte予防 講義
Vte予防 講義
 
Arterial Lactate Concentration is a major pronostic factor after elective sur...
Arterial Lactate Concentration is a major pronostic factor after elective sur...Arterial Lactate Concentration is a major pronostic factor after elective sur...
Arterial Lactate Concentration is a major pronostic factor after elective sur...
 
Chirurgie ouverte ou laparoscopique du foie : comment définir les limites ? -...
Chirurgie ouverte ou laparoscopique du foie : comment définir les limites ? -...Chirurgie ouverte ou laparoscopique du foie : comment définir les limites ? -...
Chirurgie ouverte ou laparoscopique du foie : comment définir les limites ? -...
 
Du 2016 tp biomarkers
Du 2016 tp biomarkersDu 2016 tp biomarkers
Du 2016 tp biomarkers
 
Liver Transplantation for Cholangiocarcinoma
Liver Transplantation for CholangiocarcinomaLiver Transplantation for Cholangiocarcinoma
Liver Transplantation for Cholangiocarcinoma
 
Samuel1 hbv lt du16
Samuel1 hbv lt du16Samuel1 hbv lt du16
Samuel1 hbv lt du16
 
4.11.15 GI Symposium
4.11.15 GI Symposium4.11.15 GI Symposium
4.11.15 GI Symposium
 
Portal Vein Embolization and colorectal liver met
Portal Vein Embolization and colorectal liver metPortal Vein Embolization and colorectal liver met
Portal Vein Embolization and colorectal liver met
 
Room a a01. mcgee-aki update on biomarkers and dx (en)
Room a a01. mcgee-aki update on biomarkers and dx (en)Room a a01. mcgee-aki update on biomarkers and dx (en)
Room a a01. mcgee-aki update on biomarkers and dx (en)
 

Viewers also liked

Stratégies thérapeutiques dans le petit carcinome hepatocellulaire
Stratégies thérapeutiques dans le petit carcinome hepatocellulaireStratégies thérapeutiques dans le petit carcinome hepatocellulaire
Stratégies thérapeutiques dans le petit carcinome hepatocellulaireEric Vibert, MD, PhD
 
Publier en Medecine et Science de la vie : Tirer parti de l'offre de publicat...
Publier en Medecine et Science de la vie : Tirer parti de l'offre de publicat...Publier en Medecine et Science de la vie : Tirer parti de l'offre de publicat...
Publier en Medecine et Science de la vie : Tirer parti de l'offre de publicat...Mony Claire
 
Impact Factor, H-Index, Score SIGAPS, etc...
Impact Factor, H-Index, Score SIGAPS, etc...Impact Factor, H-Index, Score SIGAPS, etc...
Impact Factor, H-Index, Score SIGAPS, etc...Mony Claire
 

Viewers also liked (20)

Difficultes d'Accès aux Soins pour les migrants
Difficultes d'Accès aux Soins pour les migrantsDifficultes d'Accès aux Soins pour les migrants
Difficultes d'Accès aux Soins pour les migrants
 
Stratégies thérapeutiques dans le petit carcinome hepatocellulaire
Stratégies thérapeutiques dans le petit carcinome hepatocellulaireStratégies thérapeutiques dans le petit carcinome hepatocellulaire
Stratégies thérapeutiques dans le petit carcinome hepatocellulaire
 
Publier en Medecine et Science de la vie : Tirer parti de l'offre de publicat...
Publier en Medecine et Science de la vie : Tirer parti de l'offre de publicat...Publier en Medecine et Science de la vie : Tirer parti de l'offre de publicat...
Publier en Medecine et Science de la vie : Tirer parti de l'offre de publicat...
 
Impact Factor, H-Index, Score SIGAPS, etc...
Impact Factor, H-Index, Score SIGAPS, etc...Impact Factor, H-Index, Score SIGAPS, etc...
Impact Factor, H-Index, Score SIGAPS, etc...
 
Organisation de la Recherche Clinique. France
Organisation de la Recherche Clinique. FranceOrganisation de la Recherche Clinique. France
Organisation de la Recherche Clinique. France
 
Infirmière de Bloc Opératoire - Chirurgie Biliaire - Rôle de l'IBODE
Infirmière de Bloc Opératoire - Chirurgie Biliaire - Rôle de l'IBODEInfirmière de Bloc Opératoire - Chirurgie Biliaire - Rôle de l'IBODE
Infirmière de Bloc Opératoire - Chirurgie Biliaire - Rôle de l'IBODE
 
La Transplantation hépatique pour les patients cirrhotiques graves (MELD > 35)
La Transplantation hépatique pour les patients cirrhotiques graves (MELD > 35)La Transplantation hépatique pour les patients cirrhotiques graves (MELD > 35)
La Transplantation hépatique pour les patients cirrhotiques graves (MELD > 35)
 
Les Nouvelles Règles de Transplantation Hépatique pour les patients ayant un ...
Les Nouvelles Règles de Transplantation Hépatique pour les patients ayant un ...Les Nouvelles Règles de Transplantation Hépatique pour les patients ayant un ...
Les Nouvelles Règles de Transplantation Hépatique pour les patients ayant un ...
 
Traitements de l'Hépatite C Chronique en 2014 pour les patients cirrhotiques ...
Traitements de l'Hépatite C Chronique en 2014 pour les patients cirrhotiques ...Traitements de l'Hépatite C Chronique en 2014 pour les patients cirrhotiques ...
Traitements de l'Hépatite C Chronique en 2014 pour les patients cirrhotiques ...
 
IBODE et TIPS
IBODE et TIPSIBODE et TIPS
IBODE et TIPS
 
Les Tests de Dépistage Rapide de l'Hépatite C : Quel impact sur la pratique m...
Les Tests de Dépistage Rapide de l'Hépatite C : Quel impact sur la pratique m...Les Tests de Dépistage Rapide de l'Hépatite C : Quel impact sur la pratique m...
Les Tests de Dépistage Rapide de l'Hépatite C : Quel impact sur la pratique m...
 
Hépatite B Chronique - Quelle stratégie pour éliminer l'Antigène HBs ?
Hépatite B Chronique - Quelle stratégie pour éliminer l'Antigène HBs ?Hépatite B Chronique - Quelle stratégie pour éliminer l'Antigène HBs ?
Hépatite B Chronique - Quelle stratégie pour éliminer l'Antigène HBs ?
 
Traitement de l'Hépatite C Chronique selon le génotype
Traitement de l'Hépatite C Chronique selon le génotypeTraitement de l'Hépatite C Chronique selon le génotype
Traitement de l'Hépatite C Chronique selon le génotype
 
Hépatite B : Comment prévenir la réactivation virale ?
Hépatite B : Comment prévenir la réactivation virale ?Hépatite B : Comment prévenir la réactivation virale ?
Hépatite B : Comment prévenir la réactivation virale ?
 
Hepatitecnouveauxantivirauxetinteractionsmedicamenteusesgpeytavin
HepatitecnouveauxantivirauxetinteractionsmedicamenteusesgpeytavinHepatitecnouveauxantivirauxetinteractionsmedicamenteusesgpeytavin
Hepatitecnouveauxantivirauxetinteractionsmedicamenteusesgpeytavin
 
Cohorteculpitacoilly
CohorteculpitacoillyCohorteculpitacoilly
Cohorteculpitacoilly
 
Quefairedevantlhyperferritinemiedusyndromemetabolique
QuefairedevantlhyperferritinemiedusyndromemetaboliqueQuefairedevantlhyperferritinemiedusyndromemetabolique
Quefairedevantlhyperferritinemiedusyndromemetabolique
 
Recommandationsafefpecvhcmbourliere
RecommandationsafefpecvhcmbourliereRecommandationsafefpecvhcmbourliere
Recommandationsafefpecvhcmbourliere
 
Quelleplacedelatepdanschcmacastilla
QuelleplacedelatepdanschcmacastillaQuelleplacedelatepdanschcmacastilla
Quelleplacedelatepdanschcmacastilla
 
Nouvellestechniquesimageriecarcinomehepatocellulairelewin
NouvellestechniquesimageriecarcinomehepatocellulairelewinNouvellestechniquesimageriecarcinomehepatocellulairelewin
Nouvellestechniquesimageriecarcinomehepatocellulairelewin
 

Similar to Donor specific HLA alloantibodies and Hepatitis C Virus in Liver Transplantation - Breackthrough to achieve long-term survival

Evaluation of kidney donor sudan 2017
Evaluation of kidney donor sudan 2017Evaluation of kidney donor sudan 2017
Evaluation of kidney donor sudan 2017FarragBahbah
 
William Dean Wallace Lung Summary Banff 2013 Meeting in Brazil
William Dean Wallace Lung Summary Banff 2013 Meeting in BrazilWilliam Dean Wallace Lung Summary Banff 2013 Meeting in Brazil
William Dean Wallace Lung Summary Banff 2013 Meeting in BrazilKim Solez ,
 
Francesco Procaccio - Italy - Tuesday 29 - Donor Risk
Francesco Procaccio - Italy - Tuesday 29 - Donor RiskFrancesco Procaccio - Italy - Tuesday 29 - Donor Risk
Francesco Procaccio - Italy - Tuesday 29 - Donor Riskincucai_isodp
 
Selection of patient for liver transplant
Selection of patient for liver transplantSelection of patient for liver transplant
Selection of patient for liver transplantApollo Hospitals
 
Acute Kidney Injury in Dengue Fever.pptx
Acute Kidney Injury in Dengue Fever.pptxAcute Kidney Injury in Dengue Fever.pptx
Acute Kidney Injury in Dengue Fever.pptxJunaid Khan
 
Acute Kidney Injury in fever.pptx
Acute Kidney Injury in fever.pptxAcute Kidney Injury in fever.pptx
Acute Kidney Injury in fever.pptxDrTapasTripathi
 
Acg guideline acute_pancreatitis_september_2013
Acg guideline acute_pancreatitis_september_2013Acg guideline acute_pancreatitis_september_2013
Acg guideline acute_pancreatitis_september_2013iberzamz
 
Liver Transplantation Overview - June 28 2013
Liver Transplantation Overview - June 28 2013Liver Transplantation Overview - June 28 2013
Liver Transplantation Overview - June 28 2013Dr. Lewis Teperman
 
Anemia Indian scenario In Chronic Kidney Disease Patients
Anemia Indian scenario In Chronic Kidney Disease Patients Anemia Indian scenario In Chronic Kidney Disease Patients
Anemia Indian scenario In Chronic Kidney Disease Patients Dr Ashutosh Ojha
 
2014 06-05 Pretransplant Evaluation for Kidney Transplantation - Pretransplan...
2014 06-05 Pretransplant Evaluation for Kidney Transplantation - Pretransplan...2014 06-05 Pretransplant Evaluation for Kidney Transplantation - Pretransplan...
2014 06-05 Pretransplant Evaluation for Kidney Transplantation - Pretransplan...Maarten Naesens
 
Is routine thromboprophylaxis warranted in all patients of tibial fracture ma...
Is routine thromboprophylaxis warranted in all patients of tibial fracture ma...Is routine thromboprophylaxis warranted in all patients of tibial fracture ma...
Is routine thromboprophylaxis warranted in all patients of tibial fracture ma...iosrjce
 
kellygarcia.positionpaperdraft
kellygarcia.positionpaperdraftkellygarcia.positionpaperdraft
kellygarcia.positionpaperdraftKelly Garcia
 
SSHC Journal Club presentation on the The Journal of Infectious Disease Volu...
SSHC Journal Club presentation on the The  Journal of Infectious Disease Volu...SSHC Journal Club presentation on the The  Journal of Infectious Disease Volu...
SSHC Journal Club presentation on the The Journal of Infectious Disease Volu...Sydney Sexual Health Centre
 
Wfumb slideseries liver elastography
Wfumb slideseries liver elastographyWfumb slideseries liver elastography
Wfumb slideseries liver elastographySuzanneCain2
 
PresentationFinal
PresentationFinalPresentationFinal
PresentationFinalLin Han
 
What is a doppler ultrasound
What is a doppler ultrasoundWhat is a doppler ultrasound
What is a doppler ultrasoundBhakti Stm
 

Similar to Donor specific HLA alloantibodies and Hepatitis C Virus in Liver Transplantation - Breackthrough to achieve long-term survival (20)

Evaluation of kidney donor sudan 2017
Evaluation of kidney donor sudan 2017Evaluation of kidney donor sudan 2017
Evaluation of kidney donor sudan 2017
 
William Dean Wallace Lung Summary Banff 2013 Meeting in Brazil
William Dean Wallace Lung Summary Banff 2013 Meeting in BrazilWilliam Dean Wallace Lung Summary Banff 2013 Meeting in Brazil
William Dean Wallace Lung Summary Banff 2013 Meeting in Brazil
 
Francesco Procaccio - Italy - Tuesday 29 - Donor Risk
Francesco Procaccio - Italy - Tuesday 29 - Donor RiskFrancesco Procaccio - Italy - Tuesday 29 - Donor Risk
Francesco Procaccio - Italy - Tuesday 29 - Donor Risk
 
Selection of patient for liver transplant
Selection of patient for liver transplantSelection of patient for liver transplant
Selection of patient for liver transplant
 
Acute Kidney Injury in Dengue Fever.pptx
Acute Kidney Injury in Dengue Fever.pptxAcute Kidney Injury in Dengue Fever.pptx
Acute Kidney Injury in Dengue Fever.pptx
 
Acute Kidney Injury in fever.pptx
Acute Kidney Injury in fever.pptxAcute Kidney Injury in fever.pptx
Acute Kidney Injury in fever.pptx
 
Acg guideline acute_pancreatitis_september_2013
Acg guideline acute_pancreatitis_september_2013Acg guideline acute_pancreatitis_september_2013
Acg guideline acute_pancreatitis_september_2013
 
Liver Transplantation Overview - June 28 2013
Liver Transplantation Overview - June 28 2013Liver Transplantation Overview - June 28 2013
Liver Transplantation Overview - June 28 2013
 
Anemia Indian scenario In Chronic Kidney Disease Patients
Anemia Indian scenario In Chronic Kidney Disease Patients Anemia Indian scenario In Chronic Kidney Disease Patients
Anemia Indian scenario In Chronic Kidney Disease Patients
 
2014 06-05 Pretransplant Evaluation for Kidney Transplantation - Pretransplan...
2014 06-05 Pretransplant Evaluation for Kidney Transplantation - Pretransplan...2014 06-05 Pretransplant Evaluation for Kidney Transplantation - Pretransplan...
2014 06-05 Pretransplant Evaluation for Kidney Transplantation - Pretransplan...
 
Ijmas 560
Ijmas 560Ijmas 560
Ijmas 560
 
Ckd 2016 100 1
Ckd 2016 100 1Ckd 2016 100 1
Ckd 2016 100 1
 
Is routine thromboprophylaxis warranted in all patients of tibial fracture ma...
Is routine thromboprophylaxis warranted in all patients of tibial fracture ma...Is routine thromboprophylaxis warranted in all patients of tibial fracture ma...
Is routine thromboprophylaxis warranted in all patients of tibial fracture ma...
 
EAST-AFNET4.pptx
EAST-AFNET4.pptxEAST-AFNET4.pptx
EAST-AFNET4.pptx
 
kellygarcia.positionpaperdraft
kellygarcia.positionpaperdraftkellygarcia.positionpaperdraft
kellygarcia.positionpaperdraft
 
SSHC Journal Club presentation on the The Journal of Infectious Disease Volu...
SSHC Journal Club presentation on the The  Journal of Infectious Disease Volu...SSHC Journal Club presentation on the The  Journal of Infectious Disease Volu...
SSHC Journal Club presentation on the The Journal of Infectious Disease Volu...
 
CLEVER Final Manuscript_JACC_17Mar2015
CLEVER Final Manuscript_JACC_17Mar2015CLEVER Final Manuscript_JACC_17Mar2015
CLEVER Final Manuscript_JACC_17Mar2015
 
Wfumb slideseries liver elastography
Wfumb slideseries liver elastographyWfumb slideseries liver elastography
Wfumb slideseries liver elastography
 
PresentationFinal
PresentationFinalPresentationFinal
PresentationFinal
 
What is a doppler ultrasound
What is a doppler ultrasoundWhat is a doppler ultrasound
What is a doppler ultrasound
 

More from Centre Hepato-Biliaire / AP-HP Hopital Paul Brousse

More from Centre Hepato-Biliaire / AP-HP Hopital Paul Brousse (20)

Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
 
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
 
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
 
Point de vue du chirurgien hépatique - M.A. Allard
Point de vue du chirurgien hépatique - M.A. AllardPoint de vue du chirurgien hépatique - M.A. Allard
Point de vue du chirurgien hépatique - M.A. Allard
 
Quoi de neuf dans les cancers primitifs du foie? - E. Vibert
Quoi de neuf dans les cancers primitifs du foie? - E. VibertQuoi de neuf dans les cancers primitifs du foie? - E. Vibert
Quoi de neuf dans les cancers primitifs du foie? - E. Vibert
 
Conférence du Président d'honneur : l'échinococcose alvéolaire - G. Mansson
Conférence du Président d'honneur : l'échinococcose alvéolaire - G. ManssonConférence du Président d'honneur : l'échinococcose alvéolaire - G. Mansson
Conférence du Président d'honneur : l'échinococcose alvéolaire - G. Mansson
 
Chirurgie guidée par la fluorescence - N. Golse
Chirurgie guidée par la fluorescence - N. GolseChirurgie guidée par la fluorescence - N. Golse
Chirurgie guidée par la fluorescence - N. Golse
 
Chirurgie de réduction tumorale des métastases hépatique non résécables de fa...
Chirurgie de réduction tumorale des métastases hépatique non résécables de fa...Chirurgie de réduction tumorale des métastases hépatique non résécables de fa...
Chirurgie de réduction tumorale des métastases hépatique non résécables de fa...
 
Déprivation veineuse portale et sus-hépatique. Indications actuelles et résul...
Déprivation veineuse portale et sus-hépatique. Indications actuelles et résul...Déprivation veineuse portale et sus-hépatique. Indications actuelles et résul...
Déprivation veineuse portale et sus-hépatique. Indications actuelles et résul...
 
Point de vue du chirurgien colorectal - S. Benoist
Point de vue du chirurgien colorectal - S. BenoistPoint de vue du chirurgien colorectal - S. Benoist
Point de vue du chirurgien colorectal - S. Benoist
 
Chirurgie hépatique sous perfusion hypothermique - D. Azoulay
Chirurgie hépatique sous perfusion hypothermique - D. AzoulayChirurgie hépatique sous perfusion hypothermique - D. Azoulay
Chirurgie hépatique sous perfusion hypothermique - D. Azoulay
 
Transplantation hépatique pour cancer: quelles tumeurs. A quelles conditions?...
Transplantation hépatique pour cancer: quelles tumeurs. A quelles conditions?...Transplantation hépatique pour cancer: quelles tumeurs. A quelles conditions?...
Transplantation hépatique pour cancer: quelles tumeurs. A quelles conditions?...
 
DPC par chirurgie mini-invasive: Où en sommes-nous? C. Salloum
DPC par chirurgie mini-invasive: Où en sommes-nous? C. SalloumDPC par chirurgie mini-invasive: Où en sommes-nous? C. Salloum
DPC par chirurgie mini-invasive: Où en sommes-nous? C. Salloum
 
Quoi de neuf dans les métastases hépatique?
Quoi de neuf dans les métastases hépatique?Quoi de neuf dans les métastases hépatique?
Quoi de neuf dans les métastases hépatique?
 
Destruction tumorale par écho-guidage optimisé - M.A. Allard
Destruction tumorale par écho-guidage optimisé - M.A. AllardDestruction tumorale par écho-guidage optimisé - M.A. Allard
Destruction tumorale par écho-guidage optimisé - M.A. Allard
 
Obésité et chirurgie HPB? Quels risques? Quelles recommandations? Quelle pris...
Obésité et chirurgie HPB? Quels risques? Quelles recommandations? Quelle pris...Obésité et chirurgie HPB? Quels risques? Quelles recommandations? Quelle pris...
Obésité et chirurgie HPB? Quels risques? Quelles recommandations? Quelle pris...
 
Quoi de neuf dans les cancers du pancréas? - G. Pittau
Quoi de neuf dans les cancers du pancréas? - G. PittauQuoi de neuf dans les cancers du pancréas? - G. Pittau
Quoi de neuf dans les cancers du pancréas? - G. Pittau
 
Quand l'intelligence artificielle s'invite au bloc opératoire Eric VIbert.pdf
Quand l'intelligence artificielle s'invite au bloc opératoire Eric VIbert.pdfQuand l'intelligence artificielle s'invite au bloc opératoire Eric VIbert.pdf
Quand l'intelligence artificielle s'invite au bloc opératoire Eric VIbert.pdf
 
Cas Clinique Sophie SAcleux.pdf
Cas Clinique Sophie SAcleux.pdfCas Clinique Sophie SAcleux.pdf
Cas Clinique Sophie SAcleux.pdf
 
En Recherche Jean Charles Duclos Vallée.pdf
En Recherche Jean Charles Duclos Vallée.pdfEn Recherche Jean Charles Duclos Vallée.pdf
En Recherche Jean Charles Duclos Vallée.pdf
 

Recently uploaded

THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1DR SETH JOTHAM
 
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...kevinkariuki227
 
MRI Artifacts and Their Remedies/Corrections.pptx
MRI Artifacts and Their Remedies/Corrections.pptxMRI Artifacts and Their Remedies/Corrections.pptx
MRI Artifacts and Their Remedies/Corrections.pptxDr. Dheeraj Kumar
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryDr Simran Deepak Vangani
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxSamar Tharwat
 
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Dr. Aryan (Anish Dhakal)
 
Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingCardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingMedicoseAcademics
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMeenakshiGursamy
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesTina Purnat
 
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cancer Institute NSW
 
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptx
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptxMALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptx
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptxKhanSabit
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale nowSherrylee83
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxdrwaque
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionGolden Helix
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgeryKafrELShiekh University
 
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON  .pptxDIGITAL RADIOGRAPHY-SABBU KHATOON  .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptxSabbu Khatoon
 
Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentabdeli bhadarva
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)Monika Kanwar
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...PhRMA
 

Recently uploaded (20)

THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
 
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...
 
MRI Artifacts and Their Remedies/Corrections.pptx
MRI Artifacts and Their Remedies/Corrections.pptxMRI Artifacts and Their Remedies/Corrections.pptx
MRI Artifacts and Their Remedies/Corrections.pptx
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric Dentistry
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
 
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
 
Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingCardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac Pumping
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptx
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergencies
 
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)
 
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptx
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptxMALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptx
MALE REPRODUCTIVE TOXICITY STUDIES(Toxicokinetics).pptx
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgery
 
Scleroderma: Treatment Options and a Look to the Future - Dr. Macklin
Scleroderma: Treatment Options and a Look to the Future - Dr. MacklinScleroderma: Treatment Options and a Look to the Future - Dr. Macklin
Scleroderma: Treatment Options and a Look to the Future - Dr. Macklin
 
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON  .pptxDIGITAL RADIOGRAPHY-SABBU KHATOON  .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
 
Anuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatmentAnuman- An inference for helpful in diagnosis and treatment
Anuman- An inference for helpful in diagnosis and treatment
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
 

Donor specific HLA alloantibodies and Hepatitis C Virus in Liver Transplantation - Breackthrough to achieve long-term survival

  • 1. Breakthrough to achieve long-term survival DSA & HCV in liver transplantation Audrey Coilly, MD Centre Hepato-Biliaire Paul Brousse Hospital, Villejuif, France
  • 2. DISCLOSURES Audrey Coilly, MD Centre Hepato-Biliaire AP-HP Hopital Paul-Brousse, Villejuif, France I have relevant financial relationships with respect to the content of this session as follows: 1.Speaker Bureau: Gilead France 2.Grant: Novartis France 3.Consultancy and Teaching: Astellas, MSD, BMS, Janssen
  • 3. How to improve long term survival in liver transplantation?How to improve long term survival in liver transplantation? Watt, KD. Am J Transpl. 2010Watt, KD. Am J Transpl. 2010 % death according to time after liver transplantation % death according to time after liver transplantation 50% 20% • Register study, n=798
  • 4. How to improve long term survival in liver transplantation?How to improve long term survival in liver transplantation? Watt, KD. Am J Transpl. 2010Watt, KD. Am J Transpl. 2010 • Register study, n=798 • From 8-years post-LT, the first cause of death is liver-related
  • 5. HCV recurrence is the first cause of death and graft loss when patients are transplanted with a positive HCV RNA HCV recurrence is the first cause of death and graft loss when patients are transplanted with a positive HCV RNA Forman, LM. Gastroenterology. 2002Forman, LM. Gastroenterology. 2002 Patient survival Graft survival 11,036 patients (UNOS registry) 11,791 LT from 1992 to 1998 1.00 0.75 0.50 0.25 0.00 1 2 3 4 5 Follow-up (years) Proportionofpatientssurviving Log-rank X2 =19.7 P<0.0001 HCV - HCV + 1.00 0.75 0.50 0.25 0.00 1 2 3 4 5 Follow-up (years) HCV - HCV + Log-rank X2 =52.85 P<0.0001Proportionofallograftssurviving 0 0
  • 6. • The detrimental effects of DSA on outcomes following solid organ transplantation have been known for many years1 • Liver transplantation is an exception but some evidence has been recently highlighted, showing that DSA could be associated with2 : Spectrum of diseases related to donor-specific HLA alloantibodies (DSA) in liver transplantation Spectrum of diseases related to donor-specific HLA alloantibodies (DSA) in liver transplantation 1- Angaswamy, N. Human Immunology. 2013 2- O’Leary, JG. Am J Transpl. 20141- Angaswamy, N. Human Immunology. 2013 2- O’Leary, JG. Am J Transpl. 2014
  • 7. 1. What are the prevalence and incidence of DSA after LT and are they impacted by HCV replication? 2. How to diagnose acute antibody-mediated rejection (AMR)? When associated with HCV recurrence? 3. What are the consequences of DSA on LT outcomes and on HCV recurrence? 4. How to prevent? When and How to treat AMR? AgendaAgenda
  • 8. 1. What are the prevalence and incidence of DSA after LT and are they impacted by HCV replication? 2. How to diagnose acute antibody-mediated rejection (AMR)? When associated to HCV recurrence? 3. What are the consequences of DSA on LT outcomes and on HCV recurrence? 4. How to prevent? When and How to treat AMR? AgendaAgenda
  • 9. Preformed DSA is quite common in LT contextPreformed DSA is quite common in LT context 1- Castillo-Rama, M. Liver Transpl. 2008 2- Kozlowski, T. Liver Transpl. 2011 3- Muro, M. Transpl Immuno. 2005 4- Fontana, M. Transpl Int. 2010 5- Taner, T. Am J Transpl. 2012 1- Castillo-Rama, M. Liver Transpl. 2008 2- Kozlowski, T. Liver Transpl. 2011 3- Muro, M. Transpl Immuno. 2005 4- Fontana, M. Transpl Int. 2010 5- Taner, T. Am J Transpl. 2012 • Several reports of monocentric, retrospective, cross-match studies in liver transplant recipients showed prevalence of DSA ranging from 5.2% to 24.2%1-4 • A prospective monocentric study5 was consistent with these reports, as DSA was found in 22.2%
  • 10. In most cases, preformed DSA disappear after liver transplantationIn most cases, preformed DSA disappear after liver transplantation 1- Taner, T. Am J Transpl. 2012 2- Dar, W. Am J Transpl. 20111- Taner, T. Am J Transpl. 2012 2- Dar, W. Am J Transpl. 2011 Among the 20 patients, only 3 had persistent DSA at 4 months post-LT1 Some reports suggest that Class I DSA were preferentially cleared*2 *In recipients of SLKT
  • 11. While preformed DSA disappear, liver recipients may develop de novo DSA While preformed DSA disappear, liver recipients may develop de novo DSA 1- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 20141- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 2014 • In a large retrospective cohort study of 749 liver transplant recipients, 8.1% developed de novo DSA 1 year post-LT1 • Another large retrospective study enrolling 267 patients have shown an incidence of de novo DSA of 9.1% (median follow-up: 110 months)2 • In both studies, de novo DSA were mainly Class II DSA (Anti-DQ)
  • 12. Risk factors of de novo DSA appearanceRisk factors of de novo DSA appearance 1- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 20141- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 2014 At one year post-LT1 In the French study, the sole predictive factor for the emergence of de novo DSAs was retransplantation (OR 3.75; 95% CI 1.28-11.05, p=0.025)2
  • 13. Risk factors of de novo DSA appearanceRisk factors of de novo DSA appearance 1- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 20141- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 2014 At one year post-LT1 In the French study, the sole predictive factor for the emergence of de novo DSAs was retransplantation (OR 3.75; 95% CI 1.28-11.05, p=0.025)2
  • 14. Risk factors of de novo DSA appearanceRisk factors of de novo DSA appearance 1- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 20141- Kaneku, H. Am J Transpl. 2013 2- Del Bello, A. Am J Transpl. 2014 At one year post-LT1 In the French study, the sole predictive factor for the emergence of de novo DSAs was retransplantation (OR 3.75; 95% CI 1.28-11.05, p=0.025)2 • None of these studies have shown differential prevalence or incidence of DSA in HCV positive patients • The use of pegylated interferon α was not a predictor of DSA appearence2
  • 15. 1. What are the prevalence and incidence of DSA after LT and are they impacted by HCV replication? 2. How to diagnose acute antibody-mediated rejection (AMR)? When associated with HCV recurrence? 3. What are the consequences of DSA on LT outcomes and on HCV recurrence? 4. How to prevent? When and How to treat AMR? AgendaAgenda
  • 16. The diagnosis of AMR is challengingThe diagnosis of AMR is challenging • Abnormalities of liver test are inconstant and non specific • In the majority of patients, the presence of DSA is not associated with rejection – Variability of DSA testing techniques – Screening: Solid-phase immunoassays (Luminex®) – The presence and specificity of antibodies is then detected using a spectrophotometer – The mean fluorescence intensity (MFI) allows a normalization and a quantification of the results
  • 17. There is no consensus concerning threshold of MFI to be considered positive There is no consensus concerning threshold of MFI to be considered positive Musat, AI. Liver Transpl. 2013Musat, AI. Liver Transpl. 2013 • Ranging from >300 to >10 000 • Prospective study enrolling 109 LT patients – Aimed to determine cut-off of MFI with the best PPV and NPV for acute rejection (<90d post-LT) -- Class I or II MFI≥300 -- Class I and II MFI<300
  • 18. Pathological examination is important to assess diagnosis of AMRPathological examination is important to assess diagnosis of AMR O’Leary, JG. Liver Transpl. 2014O’Leary, JG. Liver Transpl. 2014 • Until recently, there was no consensus concerning histological fearures of AMR • Most of the time, AMR is followed by ACR AMR - ACRAMR - ACR Persistent ARPersistent AR Chronic rejectionChronic rejection Graft LossGraft Loss
  • 19. « acute-AMR score » « acute-AMR score »  O’Leary, JG. Liver Transpl. 2014O’Leary, JG. Liver Transpl. 2014 3 LT centers, 4 blinded pathologists
  • 20. « acute-AMR score » « acute-AMR score »  O’Leary, JG. Liver Transpl. 2014O’Leary, JG. Liver Transpl. 2014 3 LT centers, 4 blinded pathologists
  • 21. Does C4d staining assist the histopathological diagnosis in liver  transplantation? Does C4d staining assist the histopathological diagnosis in liver  transplantation? 1- Colvin, RB. J Am Soc Nephrol 2007 2- Bellamy CO. Histopathology. 2007 3- Jain, A. Clin transp. 2006 4- Bouron-Dal Soglio, D. Hum Pathol 2008 5- Lunz, J. Am J Transplant. 2012 1- Colvin, RB. J Am Soc Nephrol 2007 2- Bellamy CO. Histopathology. 2007 3- Jain, A. Clin transp. 2006 4- Bouron-Dal Soglio, D. Hum Pathol 2008 5- Lunz, J. Am J Transplant. 2012 • C4d staining is well validated to  diagnose AMR in kidney  transplantation1 • In LT, interpretation of C4d staining  and practical utility is less clear2 – More sensitive in fresh tissue – C4d deposits are often seen in other  liver insults as HCV recurrence3-4 • Only obvious and diffuse staining  (strong portal vein, capillary,  periportal sinusoids)5 O’Leary, JG. Liver Transplant. 2014
  • 22. Finally, the diagnosis of AMR should be based on 4 criteriaFinally, the diagnosis of AMR should be based on 4 criteria O’Leary, JG. Am J Transpl. 2014 – Meeting reportO’Leary, JG. Am J Transpl. 2014 – Meeting report Expert opinion 1. Presence of DSA in serum 2. Histopathologic evidence of diffuse microvascular  endothelial cell injury and microvasculitis 3. Strong and diffuse positivity of C4d staining in  tissue 4. Exclusion of other causes of injury, including HCV  related-injury
  • 23. HCV recurrence could complicate the diagnosis of acute rejection and  AMR HCV recurrence could complicate the diagnosis of acute rejection and  AMR HCV Acute rejection Portal injuries Infiltrates ++ ++ Bile duct injury +/- ++ Endotheliitis - ++ Fibrosis +/++ - Parenchymal injuries Inflammation ++ + Necrosis + - Cholestasis - + Central vein endotheliitis - + Steatosis + - Acknowledgements to Dr Sebagh MAcknowledgements to Dr Sebagh M
  • 24. 1. What are the prevalence and incidence of DSA after LT and  are they impacted by HCV replication? 2. How to diagnose acute antibody-mediated rejection (AMR)?  When associated with HCV recurrence? 3. What are the consequences of DSA on LT outcomes and on  HCV recurrence? 4. How to prevent? When and How to treat AMR? AgendaAgenda
  • 25. De novo DSAs decrease both patient and graft survivalDe novo DSAs decrease both patient and graft survival • Patients with de novo DSA develop AMR in 23.8%1 1- Del Bello, A. Am J Transpl. 2014 2- Kaneku, H. Am J Transpl. 20131- Del Bello, A. Am J Transpl. 2014 2- Kaneku, H. Am J Transpl. 2013 Patient survival2 Graft survival2
  • 26. Available data concerning the impact of preformed DSA on graft and  overall survival are contradictory Available data concerning the impact of preformed DSA on graft and  overall survival are contradictory 1- Gordon, RD. Surgery. 1986 2- Moore, SB. Transplant Proc. 1987 3- Ogura, K. Transplant Proc. 1992 4- Takaya, S. . Transplant Proc. 1991 5- Goh, A. Liver Transplant. 2010 6- Castillo-Rama, M. Liver Transpl. 2008 1- Gordon, RD. Surgery. 1986 2- Moore, SB. Transplant Proc. 1987 3- Ogura, K. Transplant Proc. 1992 4- Takaya, S. . Transplant Proc. 1991 5- Goh, A. Liver Transplant. 2010 6- Castillo-Rama, M. Liver Transpl. 2008 • Several ancient reports found that a positive cross-match was  unrelated to LT outcomes1,2 • … But many others demonstrated an increased graft loss rates3-6
  • 27. Class II DSA (preformed or de novo) are independent predictor of  patient death and allograft loss Class II DSA (preformed or de novo) are independent predictor of  patient death and allograft loss • Preformed class II DSA have been shown to be associated with early AR1 • In a monocentric retrospective study analyzing 86 SLKT patients2 , class II DSA  (preformed or de novo) increased AMR and ACR of the liver and kidney  grafts 1- O’Leary, JG. Liver Transpl. 2013 2- O’Leary, JG. Am J Transpl. 20131- O’Leary, JG. Liver Transpl. 2013 2- O’Leary, JG. Am J Transpl. 2013
  • 28. DSA are associated with fibrosis progression in HCV positive recipientsDSA are associated with fibrosis progression in HCV positive recipients • In this monocentric retrospective study analyzing 507 LT patients • Preformed Class I and II DSAs were associated with lower survival • de novo DSA are limit but unsignificant regarding fibrosis progression O’Leary, JG. Liver Transplant. 2014O’Leary, JG. Liver Transplant. 2014
  • 29. 1. What are the prevalence and incidence of DSA after LT and are they impacted by HCV replication? 2. How to diagnose acute antibody-mediated rejection (AMR)? When associated with HCV recurrence? 3. What are the consequences of DSA on LT outcomes and on HCV recurrence? 4. How to prevent? When and How to treat AMR? AgendaAgenda
  • 30. « Prevention is better than cure »: Before liver transplantation« Prevention is better than cure »: Before liver transplantation 1- Curry, MP. ILTS 2014. Oral #137 2- O’Leary, JG. Am J Transpl. 20131- Curry, MP. ILTS 2014. Oral #137 2- O’Leary, JG. Am J Transpl. 2013 HCV: Achieve SVR before LT • Not always possible with IFN-based regimen • Most of patients will be able to achieve SVR before LT • Post-LT SVR12: 70% Preformed DSA Liver transplant (up to 48 weeks) SOF 400 mg/day + RBV 1000–1200 mg/day SOF 400 mg/day + RBV 1000–1200 mg/day Undergoing LT for HCC 2° to HCV1 N=61 Undergoing LT for HCC 2° to HCV1 N=61 • Evidence does not advocate to contraindicate LT when there is a positive crossmatch, nor to delay LT awaiting the results • Avoid preformed Class II DSA in combined liver- kidney transplantation (MFI>10,000)2
  • 31. « Prevention is better than cure »: After liver transplantation« Prevention is better than cure »: After liver transplantation • In my opinion, treating HCV recurrence based on IFN-free regimen is mandatory without waiting a significant fibrosis on the liver graft Preformed DSA Strict monitoring: -Liver test when tapering IS -Retest DSA: timing? -Protocol liver biopsies: 1, 2 and 5 years
  • 32. « Prevention is better than cure »: After liver transplantation« Prevention is better than cure »: After liver transplantation • In my opinion, treating HCV recurrence based on IFN-free regimen is mandatory without waiting a significant firbrosis on the liver graft De novo or persistent DSA *Anti-humoral agents and techniques as plasmapheresis, IV immune globuline, rituximab, bortezomib*Anti-humoral agents and techniques as plasmapheresis, IV immune globuline, rituximab, bortezomib
  • 33. • The prevalence of preformed DSA is about 20% and the incidence of de novo DSA is about 10% in LT • DSA are associated with several graft diseases, mainly AMR but diagnosis was made on histological features+/-C4d staining • De novo DSA and preformed class II DSA, especially with high MFI, seem to pejoratively influence outcomes after LT • When associated with HCV, DSA worsen fibrosis progression • Thanks to antiviral IFN-free regimen, therapeutic strategies of DSA positivity and/or AMR will not differ from HCV- recipients, but need to be evaluated in prospective studies ConclusionConclusion

Editor's Notes

  1. Early and late stage as well
  2. Utiliser DSA against Class I, etc…
  3. Utiliser DSA against Class I, etc…
  4. Utiliser DSA against Class I, etc…
  5. Utiliser DSA against Class I, etc…
  6. Utiliser DSA against Class I, etc…
  7. Utiliser DSA against Class I, etc…
  8. Utiliser DSA against Class I, etc…
  9. Utiliser DSA against Class I, etc…
  10. Utiliser DSA against Class I, etc…
  11. Utiliser DSA against Class I, etc…
  12. Utiliser DSA against Class I, etc…
  13. Utiliser DSA against Class I, etc…
  14. Utiliser DSA against Class I, etc…
  15. Utiliser DSA against Class I, etc…
  16. Utiliser DSA against Class I, etc…
  17. Utiliser DSA against Class I, etc…
  18. Utiliser DSA against Class I, etc…
  19. Utiliser DSA against Class I, etc…
  20. Utiliser DSA against Class I, etc…
  21. Bien parlé de la prevention: eviter tf, adherence etc
  22. Utiliser DSA against Class I, etc…
  23. Utiliser DSA against Class I, etc…
  24. Utiliser DSA against Class I, etc…